^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SV-102

    i
    Other names: SV-102, SYNC-T SV-102
    Company:
    Syncromune
    Drug class:
    Immunomodulator
    Related drugs:
    23d
    A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=91, Recruiting, Syncromune, Inc. | N=70 --> 91 | Trial completion date: Dec 2027 --> Apr 2028 | Trial primary completion date: Dec 2027 --> Apr 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation
    |
    SV-102
    1year
    A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Syncromune, Inc. | Phase classification: P1 --> P2 | N=28 --> 70
    Phase classification • Enrollment change
    |
    SV-102
    over1year
    A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=28, Recruiting, Syncromune, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SV-102
    almost2years
    A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Syncromune, Inc.
    New P1 trial • Metastases
    |
    SV-102